Cargando…

Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model

Pancreatic cancer (PC) is one of the most aggressive malignancies. A combination of targeted therapies could increase the therapeutic efficacy in tumors with heterogeneous target expression. Overexpression of the human epidermal growth factor receptor type 3 (HER3) and the epithelial cell adhesion m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Tianqi, Schulga, Alexey, Konovalova, Elena, Rinne, Sara S., Zhang, Hongchao, Vorontsova, Olga, Orlova, Anna, Deyev, Sergey M., Tolmachev, Vladimir, Vorobyeva, Anzhelika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917732/ https://www.ncbi.nlm.nih.gov/pubmed/36769161 http://dx.doi.org/10.3390/ijms24032838

Ejemplares similares

Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1
por: Vorobyeva, Anzhelika, et al.
Publicado: (2020)

Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1
por: Vorobyeva, Anzhelika, et al.
Publicado: (2020)

Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model
por: Xu, Tianqi, et al.
Publicado: (2021)

Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1
por: Deyev, Sergey M., et al.
Publicado: (2021)

Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging
por: Vorobyeva, Anzhelika, et al.
Publicado: (2019)

On the prevention of kidney uptake of radiolabeled DARPins
por: Altai, Mohamed, et al.
Publicado: (2020)

Direct In Vivo Comparison of (99m)Tc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy
por: Tolmachev, Vladimir, et al.
Publicado: (2022)

Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2
por: Vorobyeva, Anzhelika, et al.
Publicado: (2019)

Phase I Trial of (99m)Tc-(HE)(3)-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer
por: Bragina, Olga, et al.
Publicado: (2022)

Optimal composition and position of histidine-containing tags improves biodistribution of (99m)Tc-labeled DARPin G3
por: Vorobyeva, Anzhelika, et al.
Publicado: (2019)

EpCAM-Binding DARPins for Targeted Photodynamic Therapy of Ovarian Cancer
por: van den Brand, Dirk, et al.
Publicado: (2020)

Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with (99m)Tc for Radionuclide Imaging of HER2 Expression in Cancer
por: Larkina, Mariia, et al.
Publicado: (2022)

Visualization of epithelial cell adhesion molecule-expressing renal cell carcinoma xenografts using designed ankyrin repeat protein Ec1 labelled with (99m)Tc and (125)I
por: Tolmachev, Vladimir, et al.
Publicado: (2022)

Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors
por: Vorobyeva, Anzhelika, et al.
Publicado: (2018)

Epithelial cell adhesion molecule-targeting designed ankyrin repeat protein-toxin fusion Ec1-LoPE exhibits potent cytotoxic action in prostate cancer cells
por: Xu, Tianqi, et al.
Publicado: (2022)

Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart
por: Garousi, Javad, et al.
Publicado: (2022)

The detection of EpCAM(+) and EpCAM(–) circulating tumor cells
por: Wit, Sanne de, et al.
Publicado: (2015)

Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas
por: Fong, Dominic, et al.
Publicado: (2014)

HER2-Specific Targeted Toxin DARPin-LoPE: Immunogenicity and Antitumor Effect on Intraperitoneal Ovarian Cancer Xenograft Model
por: Sokolova, Evgeniya A., et al.
Publicado: (2019)

Radionuclide Therapy of HER2-Expressing Xenografts Using [(177)Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab
por: Liu, Yongsheng, et al.
Publicado: (2023)

Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules
por: Rinne, Sara S., et al.
Publicado: (2020)

Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule (188)Re-ZHER2:41071
por: Liu, Yongsheng, et al.
Publicado: (2022)

Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody–DM1 Drug Conjugates
por: Ding, Haozhong, et al.
Publicado: (2019)

Expression of EpCAM in uveal melanoma
por: Odashiro, Danilo N, et al.
Publicado: (2006)

Biology and clinical relevance of EpCAM
por: Keller, Laura, et al.
Publicado: (2019)

EpCAM as Modulator of Tissue Plasticity
por: Fagotto, François
Publicado: (2020)

EpCAM(high) and EpCAM(low) circulating tumor cells in metastatic prostate and breast cancer patients
por: de Wit, Sanne, et al.
Publicado: (2018)

Dual Targeting of Cancer Cells with DARPin-Based Toxins for Overcoming Tumor Escape
por: Shramova, Elena, et al.
Publicado: (2020)

Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake
por: Rosestedt, Maria, et al.
Publicado: (2019)

HER3 PET Imaging: (68)Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to (89)Zr-Labeled Antibody and Antibody-Fragment-Based Tracers
por: Rinne, Sara S., et al.
Publicado: (2021)

EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex
por: Subramanian, Nithya, et al.
Publicado: (2015)

The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
por: Yin, Wen, et al.
Publicado: (2021)

Current View on EpCAM Structural Biology
por: Gaber, Aljaž, et al.
Publicado: (2020)

Evolution of Thyroglobulin Loop Kinetics in EpCAM
por: Chen, Serena H., et al.
Publicado: (2021)

Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model
por: Xu, Tianqi, et al.
Publicado: (2020)

EpCAM expression in squamous cell carcinoma of the uterine cervix detected by monoclonal antibody to the membrane-proximal part of EpCAM
por: Chantima, Warangkana, et al.
Publicado: (2017)

Correction to: EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex
por: Subramanian, Nithya, et al.
Publicado: (2020)

Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution
por: Ding, Haozhong, et al.
Publicado: (2021)

EpCAM Knockdown Alters MicroRNA Expression in Retinoblastoma- Functional Implication of EpCAM Regulated MiRNA in Tumor Progression
por: Beta, Madhu, et al.
Publicado: (2014)

Antitumor activities of a defucosylated anti-EpCAM monoclonal antibody in colorectal carcinoma xenograft models
por: Li, Guanjie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bl1j7td9vukgi5heh0m9pfl1ss